Treatment Action Group Statement on BCG Vaccine and COVID-19
Treatment Action Group (TAG) cautions that widespread media reports that the baccille Calmette–Guérin (BCG) vaccine may be protective against COVID-19 need to be read with caution.
Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa
An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.
Statement on U.S. FDA Report Highlighting Gaps in Pediatric Research
Treatment Action Group (TAG) welcomes a report released last week by the U.S. Food and Drug Administration (FDA) that highlights urgent gaps in pediatric research. This report confirms that we are missing critical information necessary to treat children affected by orphan diseases.
Whose Intellect? Whose Property? A Blueprint for Bringing Down the Pharma IP House of Cards
By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American…
Research Priorities for Pediatric Tuberculosis
This document (not a TAG publication) presents an overview of paediatric TB research efforts already underway and their limitations; and highlights priorities for future research initiatives in epidemiology, basic science, prevention, diagnosis, treatment and operational research.
TAGline Spring 2018
Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.
Community Advocates Letter to U.S. Government Partners of the Conference on Retroviruses and Opportunistic Infections
We are writing to express serious concern and dismay regarding the shutting down of the website for the Conference on Retroviruses and Opportunistic Infections (CROI).
Letter to the EMA: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)
May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…